NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, News & Analysis

$0.99
+0.03 (+3.12 %)
(As of 08/26/2019 01:38 AM ET)
Today's Range
$0.93
Now: $0.9918
$1.04
50-Day Range
$0.9460
MA: $1.41
$1.84
52-Week Range
$0.78
Now: $0.9918
$7.26
Volume2.23 million shs
Average Volume728,747 shs
Market Capitalization$45.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLCM
CUSIPN/A
Phone832-384-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 million
Book Value$0.66 per share

Profitability

Net Income$-98,040,000.00
Net Margins-4,081.44%

Miscellaneous

Employees173
Market Cap$45.87 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.


Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) issued its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.04. The biopharmaceutical company earned $1.39 million during the quarter, compared to the consensus estimate of $0.23 million. Bellicum Pharmaceuticals had a negative net margin of 4,081.44% and a negative return on equity of 169.33%. View Bellicum Pharmaceuticals' Earnings History.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Bellicum Pharmaceuticals.

Has Bellicum Pharmaceuticals been receiving favorable news coverage?

Press coverage about BLCM stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Bellicum Pharmaceuticals.

Who are some of Bellicum Pharmaceuticals' key competitors?

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), NVIDIA (NVDA), FireEye (FEYE), ACADIA Pharmaceuticals (ACAD) and General Cannabis (CANN).

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
  • Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
  • Mr. Thomas J. Farrell, Consultant (Age 56)
  • Mr. Atabak Mokari, Chief Financial Officer (Age 42)
  • Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (7.31%), Nikko Asset Management Americas Inc. (4.55%), Sumitomo Mitsui Trust Holdings Inc. (4.55%), Vanguard Group Inc. (4.06%), Renaissance Technologies LLC (3.38%) and ARK Investment Management LLC (2.78%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer, Jon P Stonehouse and Richard A Fair. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Which institutional investors are selling Bellicum Pharmaceuticals stock?

BLCM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Vanguard Group Inc., Bank of New York Mellon Corp, ARK Investment Management LLC, Charles Schwab Investment Management Inc., Wells Fargo & Company MN and Northern Trust Corp. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Which institutional investors are buying Bellicum Pharmaceuticals stock?

BLCM stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, Jane Street Group LLC, Paloma Partners Management Co, GSA Capital Partners LLP, AXA and Algert Global LLC. Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Jon P Stonehouse and Richard A Fair. View Insider Buying and Selling for Bellicum Pharmaceuticals.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $0.9918.

How big of a company is Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals has a market capitalization of $45.87 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.View Additional Information About Bellicum Pharmaceuticals.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is http://www.bellicum.com/.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]


MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/26/2019 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel